NASDAQ
NBRV

Nabriva Therapeutics AG

Biotechnology & Medical Research
Healthcare

Prices are adjusted according to historical splits.

Nabriva Therapeutics AG Stock Price

Vitals

Today's Low:
$0.42
Today's High:
$0.8
Open Price:
$0.6927
52W Low:
$0.42
52W High:
$8.45
Prev. Close:
$0.69
Volume:
36891

Company Statistics

Market Cap.:
$4.55 million
Book Value:
-1.361
Revenue TTM:
$36.51 million
Operating Margin TTM:
-128.77%
Gross Profit TTM:
$-10226000
Profit Margin:
-148.11%
Return on Assets TTM:
-65.2%
Return on Equity TTM:
-268.53%

Company Profile

Nabriva Therapeutics AG had its IPO on 2015-09-18 under the ticker symbol NBRV.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Nabriva Therapeutics AG has a staff strength of 39 employees.

Stock update

Shares of Nabriva Therapeutics AG opened at $0.69 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.42 - $0.8, and closed at $0.49.

This is a -28.99% slip from the previous day's closing price.

A total volume of 36,891 shares were traded at the close of the day’s session.

In the last one week, shares of Nabriva Therapeutics AG have slipped by -24.62%.

Nabriva Therapeutics AG's Key Ratios

Nabriva Therapeutics AG has a market cap of $4.55 million, indicating a price to book ratio of 0.2392 and a price to sales ratio of 0.166.

In the last 12-months Nabriva Therapeutics AG’s revenue was $36.51 million with a gross profit of $-10226000 and an EBITDA of $-46847000. The EBITDA ratio measures Nabriva Therapeutics AG's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nabriva Therapeutics AG’s operating margin was -128.77% while its return on assets stood at -65.2% with a return of equity of -268.53%.

In Q1, Nabriva Therapeutics AG’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5.4%.

Nabriva Therapeutics AG’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.06

Its diluted EPS in the last 12-months stands at $-19.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.06. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nabriva Therapeutics AG’s profitability.

Nabriva Therapeutics AG stock is trading at a EV to sales ratio of 0.0009 and a EV to EBITDA ratio of 0.0523. Its price to sales ratio in the trailing 12-months stood at 0.166.

Nabriva Therapeutics AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$31.77 million
Total Liabilities
$27.61 million
Operating Cash Flow
$0
Capital Expenditure
$9000
Dividend Payout Ratio
0%

Nabriva Therapeutics AG ended 2024 with $31.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $31.77 million while shareholder equity stood at $3.29 million.

Nabriva Therapeutics AG ended 2024 with $0 in deferred long-term liabilities, $27.61 million in other current liabilities, 32000.00 in common stock, $-652861000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.41 million and cash and short-term investments were $12.41 million. The company’s total short-term debt was $4,833,000 while long-term debt stood at $345000.00.

Nabriva Therapeutics AG’s total current assets stands at $31.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $6.74 million compared to accounts payable of $5.43 million and inventory worth $9.68 million.

In 2024, Nabriva Therapeutics AG's operating cash flow was $0 while its capital expenditure stood at $9000.

Comparatively, Nabriva Therapeutics AG paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.49
52-Week High
$8.45
52-Week Low
$0.42
Analyst Target Price
$1

Nabriva Therapeutics AG stock is currently trading at $0.49 per share. It touched a 52-week high of $8.45 and a 52-week low of $8.45. Analysts tracking the stock have a 12-month average target price of $1.

Its 50-day moving average was $1.06 and 200-day moving average was $1.54 The short ratio stood at 8.58 indicating a short percent outstanding of 0%.

Around 96.8% of the company’s stock are held by insiders while 877.7% are held by institutions.

Frequently Asked Questions About Nabriva Therapeutics AG

The stock symbol (also called stock or share ticker) of Nabriva Therapeutics AG is NBRV

The IPO of Nabriva Therapeutics AG took place on 2015-09-18

Similar Industry Stocks (Biotechnology & Medical Research)

Last Price
Chg
Chg%
Navient Corp (NAVI)
$17.36
0.09
+0.52%
Oblong Inc (OBLG)
$0.73
0
+0.4%
$818.75
-30.1
-3.55%
DCM Shriram Limited (DCMSHRIRAM)
$980.1
-37.65
-3.7%
$618.1
-11.7
-1.86%
$2.05
-0.08
-3.76%
$0.34
0.01
+2.7%
$486.6
-49.05
-9.16%
$37.3
-1.71
-4.38%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Address

25-28 North Wall Quay, Dublin, Ireland, 1